Dunad Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Dunad Therapeutics's estimated annual revenue is currently $3.3M per year.
- Dunad Therapeutics's estimated revenue per employee is $77,500
Employee Data
- Dunad Therapeutics has 43 Employees.
- Dunad Therapeutics grew their employee count by 48% last year.
Dunad Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder, acting CEO, CSO | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
3 | SVP Drug Discovery | Reveal Email/Phone |
4 | Head Finance and Operations | Reveal Email/Phone |
5 | Director Medicinal Chemistry | Reveal Email/Phone |
6 | Director Computational Sciences | Reveal Email/Phone |
7 | Chief Financial Officer | Reveal Email/Phone |
8 | Senior Data Manager | Reveal Email/Phone |
Dunad Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.2M | 54 | 13% | $16M | N/A |
#2 | $1.2M | 16 | 45% | $10M | N/A |
#3 | $2.7M | 35 | 3% | $13.9M | N/A |
#4 | $3.3M | 43 | 48% | N/A | N/A |
#5 | $3.3M | 43 | 13% | $16M | N/A |
#6 | $2.9M | 38 | 19% | $11.3M | N/A |
#7 | $0.9M | 12 | 9% | N/A | N/A |
What Is Dunad Therapeutics?
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted oral protein degradation therapies. Dunad’s platform enables selective degradation via direct target modification using tunable mono-valent small molecules, allowing for the development of more drug-like, orally bioavailable and CNS-accessible protein degraders.
keywords:N/AN/A
Total Funding
43
Number of Employees
$3.3M
Revenue (est)
48%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $8.7M | 43 | 30% | N/A |
#2 | $3.3M | 43 | -57% | $65M |
#3 | $5M | 43 | -9% | N/A |
#4 | $15M | 43 | -19% | N/A |
#5 | $11.1M | 43 | -4% | N/A |